Kelun-Biotech Presents Promising Phase III Lung Cancer Study Results at ASCO
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the results of their Phase III clinical study, OptiTROP-Lung05, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study evaluated the efficacy of sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab (KEYTRUDA®) as a first-line treatment for non-small cell lung cancer (NSCLC) with a PD-L1 Tumor Proportion Score of 1% or higher. The study involved 413 patients and demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) when compared to pembrolizumab alone. The combination therapy showed a median PFS that was not reached, compared to 5.7 months for pembrolizumab alone, and a 12-month PFS rate of 62.4% versus 29.0%. The study also reported a positive trend in OS, with a 12-month OS rate of 80.4% versus 68.9%. The safety profile of the combination was manageable, with no new safety signals identified. 
